论文部分内容阅读
目的 :探讨血脂康降脂治疗及预防冠心病的机制。方法 :测定 38例高胆固醇血症患者在服药前及服药后第 4、8周与 2 0例正常对照者的血脂及血清一氧化氮 (NO)水平。结果 :①治疗前高胆固醇组与对照组相比 ,血清总胆固醇 (TC)、低密度脂蛋白胆固醇 (LDL C)明显升高 ,NO明显降低。②血脂康治疗 4周后 ,血清TC、LDL C明显下降 ,NO无改变 ,至第 8周 ,血清NO显著上升。③治疗后LDL C下降值与NO上升值呈负相关 (r=- 0 .6 9,P <0 .0 5 )。结论 :血脂康除有效降脂外 ,还能提高血清NO水平 ;血清NO水平随LDL C降低而上升 ,可能是降脂治疗及预防冠心病发生的重要机制之一
Objective: To explore the mechanism of Xuezhikang lipid-lowering therapy and prevention of coronary heart disease. Methods: The levels of serum lipids and serum nitric oxide (NO) in 38 hypercholesterolemic patients before and after 4 and 8 weeks and 20 normal controls were measured. Results: Compared with the control group, the levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL C) and NO in the high cholesterol group before treatment were significantly decreased. ② Xuezhikang treatment for 4 weeks, serum TC, LDL C decreased significantly, NO unchanged, to the first 8 weeks, serum NO increased significantly. ③ After treatment, the decrease of LDL C was negatively correlated with the increase of NO (r = - 0.96, P <0.05). Conclusion: In addition to effective lipid-lowering therapy, Xuezhikang can also increase serum NO level. Serum NO level increases with the decrease of LDL-C, which may be one of the important mechanisms of lipid-lowering therapy and prevention of coronary heart disease